stockrowAutolus Therapeutics PLC Sponsored ADR
AUTL Healthcare Biotechnology
Autolus Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $75.4 million, up 644.9% from fiscal 2024.
- Revenue
- +118.4%
- EPS
- +16.7%
- Free cash flow
- +67.6%
Quarter to June 2026, against a year earlier
Follow AUTL
Alert me
Autolus Therapeutics PLC Sponsored ADR (AUTL) EV/Sales
As of 3 November 2026, Autolus Therapeutics PLC Sponsored ADR (AUTL) trades at a EV/Sales of 2.2×. Over the past ten years it has ranged from −30.7× (June 2022) to 781× (January 2019); the current reading is higher than 24% of that period. That is below the Biotechnology industry median of 9.5× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.9× | (31.32%) |
| FY2024 | 5.7× | (96.85%) |
| FY2023 | 181× | — |
| FY2022 | −28.4× | — |
| FY2021 | 34.3× | (83.53%) |
| FY2020 | 208× | 59.17% |
| FY2019 | 131× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.6× | 16.68% |
| Mar 2026 | 2.2× | (43.80%) |
| Dec 2025 | 3.9× | 74.22% |
| Sep 2025 | 2.2× | (55.32%) |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AVTX Avalo Therapeutics, Inc. compare | −57.2× |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| ZURA Zura Bio Limited compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR | 2.2× |
| FENC Adherex Technologies Inc. compare | 5.8× |
| ALLO Allogene Therapeutics, Inc. compare | 8.3× |
| TRXB TRex Bio Inc. compare | — |
| Biotechnology industry median | 9.5× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)